Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03719664
- Locations
- πΊπΈ
ABT-3BNC117_201 Investigational Site, New York, New York, United States
A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT02436824
- Locations
- πΊπΈ
Atco Medical Associates, P.C., Atco, New Jersey, United States
πΊπΈUniMed Center, East Brunswick, New Jersey, United States
πΊπΈGeorgia Institute for Clinical Research,LLC, Marietta, Georgia, United States
Test Albuvirtide in Experienced Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 418
- Registration Number
- NCT02369965
- Locations
- π¨π³
The Third People'S Hospital Of Shenzhen, Shenzhen, Guangdong, China
π¨π³The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
π¨π³Beijing Youan Hospital, Capital medical university, Beijing, Beijing, China
Β© Copyright 2024. All Rights Reserved by MedPath